New Drug for Cervical Cancer Boosts Survival Rates by Over 30%
A new prescription medicine called TIVDAK (tisotumab vedotin) has shown promising results in phase 3 global trials for treating cervical cancer. Compared to chemotherapy, TIVDAK was linked to a 30% reduction in the risk of death and a 33% decrease in the risk of worsening disease or death. The drug also demonstrated an improved objective response rate and disease control rate. TIVDAK attacks a specific protein on cancer cells, allowing chemotherapy to be delivered more precisely and with fewer side effects. Doctors involved in the trials believe TIVDAK is a game-changer and hope for full FDA approval in the near future.